NASDAQ:FLXN - Flexion Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.13
  • Forecasted Upside: 120.67 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
▼ -0.04 (-0.44%)

This chart shows the closing price for FLXN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Flexion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FLXN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FLXN

Analyst Price Target is $20.13
▲ +120.67% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Flexion Therapeutics in the last 3 months. The average price target is $20.13, with a high forecast of $35.00 and a low forecast of $14.00. The average price target represents a 120.67% upside from the last price of $9.12.

This chart shows the closing price for FLXN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Flexion Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2021Credit Suisse GroupLower Price TargetOutperform$17.00 ➝ $14.00High
4/18/2021Royal Bank of CanadaReiterated RatingBuyHigh
4/14/2021Credit Suisse GroupLower Price TargetOutperform$18.00 ➝ $17.00High
4/14/2021Raymond JamesLower Price TargetStrong-Buy$18.00 ➝ $16.00High
4/14/2021HC WainwrightReiterated RatingBuyHigh
3/11/2021Credit Suisse GroupLower Price TargetOutperform$19.00 ➝ $18.00Low
1/27/2021Wells Fargo & CompanyLower Price TargetOverweight$16.00 ➝ $15.00Low
12/14/2020Needham & Company LLCReiterated RatingBuyHigh
11/30/2020HC WainwrightReiterated RatingBuyLow
11/5/2020Raymond JamesLower Price TargetStrong-Buy$19.00 ➝ $18.00High
11/5/2020BMO Capital MarketsLower Price TargetOutperform$23.00 ➝ $22.00High
8/20/2020The Goldman Sachs GroupInitiated CoverageNeutral$15.00Low
8/6/2020HC WainwrightReiterated RatingBuy$25.00High
8/6/2020Northland SecuritiesInitiated CoverageBuy$35.00High
7/30/2020OppenheimerInitiated CoverageOutperform$19.00High
7/29/2020Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$19.00High
7/15/2020HC WainwrightReiterated RatingBuy$25.00High
6/25/2020HC WainwrightInitiated CoverageBuy$25.00High
6/2/2020Northland SecuritiesInitiated CoverageBuy$35.00Low
5/26/2020GuggenheimInitiated CoverageBuy$20.00High
5/8/2020Needham & Company LLCLower Price TargetBuy$30.00 ➝ $20.00High
5/8/2020Royal Bank of CanadaLower Price TargetOutperform$20.00 ➝ $18.00High
4/30/2020Needham & Company LLCLower Price TargetBuy$36.00 ➝ $30.00Medium
4/27/2020Northland SecuritiesInitiated CoverageBuy$35.00High
4/27/2020Raymond JamesLower Price TargetStrong-Buy$23.00 ➝ $20.00High
4/2/2020BenchmarkLower Price TargetBuy$25.00 ➝ $17.00Medium
4/1/2020Needham & Company LLCReiterated RatingBuy$36.00Medium
12/27/2019Needham & Company LLCReiterated RatingBuy$36.00Medium
12/27/2019BMO Capital MarketsReiterated RatingBuy$29.00Medium
12/27/2019BenchmarkBoost Price TargetBuy$19.00 ➝ $25.00High
12/27/2019Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $28.00High
12/5/2019Craig HallumInitiated CoverageBuy$24.00Low
11/25/2019BTIG ResearchInitiated CoverageBuy$27.00High
9/10/2019Northland SecuritiesSet Price TargetBuy$20.00High
5/9/2019Northland SecuritiesReiterated RatingBuy$20.00High
5/9/2019BenchmarkUpgradeHold ➝ Buy$19.00High
4/11/2019LaidlawSet Price TargetBuy$18.00Low
4/10/2019Wells Fargo & CompanyReiterated RatingBuyLow
3/28/2019Raymond JamesReiterated RatingBuyHigh
3/1/2019Northland SecuritiesReiterated RatingBuy$20.00High
1/4/2019BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$36.00 ➝ $34.00High
1/4/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $36.00High
1/4/2019BenchmarkDowngradeBuy ➝ Hold$11.49High
12/28/2018Wells Fargo & CompanyReiterated RatingBuy$26.00High
12/2/2018Wells Fargo & CompanySet Price TargetBuy$39.00Medium
11/5/2018Wells Fargo & CompanyReiterated RatingBuyLow
10/22/2018Wells Fargo & CompanySet Price TargetBuy$39.00High
6/28/2018BenchmarkInitiated CoverageBuy$39.00Medium
5/5/2018Wells Fargo & CompanyReiterated RatingBuyLow
4/26/2018Wells Fargo & CompanyReiterated RatingBuyMedium
4/3/2018Wells Fargo & CompanySet Price TargetBuy$39.00Low
3/9/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$37.00 ➝ $36.00Low
2/1/2018Berenberg BankInitiated CoverageBuy$42.00High
11/10/2017Northland SecuritiesReiterated RatingBuy$40.00N/A
10/30/2017Wells Fargo & CompanySet Price TargetBuy$39.00N/A
10/29/2017Royal Bank of CanadaSet Price TargetBuy$44.00N/A
10/10/2017LaidlawReiterated RatingBuy$35.00 ➝ $38.00N/A
10/10/2017Janney Montgomery ScottBoost Price TargetBuy ➝ Fair Value$570.00N/A
10/9/2017BMO Capital MarketsReiterated RatingOutperform$35.00 ➝ $37.00N/A
10/9/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$36.00 ➝ $42.00N/A
10/6/2017Wells Fargo & CompanySet Price TargetBuy$32.00 ➝ $39.00N/A
10/4/2017Northland SecuritiesReiterated RatingBuy$40.00Medium
9/17/2017Needham & Company LLCReiterated RatingBuy$36.00High
9/11/2017Royal Bank of CanadaSet Price TargetBuy$44.00Low
8/24/2017Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$40.00High
8/11/2017BMO Capital MarketsReiterated RatingBuyHigh
8/10/2017Needham & Company LLCReiterated RatingBuy$34.00 ➝ $36.00Low
8/10/2017Royal Bank of CanadaReiterated RatingOutperform$44.00Low
7/12/2017Janney Montgomery ScottReiterated RatingBuy$30.00 ➝ $35.00High
7/7/2017Royal Bank of CanadaReiterated RatingBuy$44.00Low
6/27/2017BMO Capital MarketsReiterated RatingBuyHigh
6/12/2017Cantor FitzgeraldSet Price TargetBuy$40.00Low
5/22/2017Cantor FitzgeraldSet Price TargetBuy$40.00Medium
5/15/2017Needham & Company LLCReiterated RatingBuy$34.00High
5/4/2017Cantor FitzgeraldSet Price TargetBuy$40.00High
4/26/2017Cantor FitzgeraldReiterated RatingBuy$34.00High
3/26/2017Royal Bank of CanadaSet Price TargetBuy$44.00High
3/25/2017Wells Fargo & CompanyReiterated RatingOutperform$30.00Medium
3/25/2017Cantor FitzgeraldReiterated RatingOverweight$34.00Medium
3/14/2017Cantor FitzgeraldReiterated RatingBuy$37.00 ➝ $34.00High
3/11/2017Royal Bank of CanadaReiterated RatingOutperform$44.00N/A
3/11/2017Janney Montgomery ScottReiterated RatingBuy$30.00N/A
2/23/2017Cantor FitzgeraldSet Price TargetBuy$37.00N/A
2/7/2017Cantor FitzgeraldSet Price TargetBuy$37.00N/A
2/7/2017BMO Capital MarketsReiterated RatingPositive$33.00N/A
1/17/2017Cantor FitzgeraldSet Price TargetBuy$37.00N/A
12/22/2016Raymond JamesInitiated CoverageStrong-Buy$35.00N/A
12/15/2016BMO Capital MarketsReiterated RatingOutperform$33.00N/A
12/12/2016Cantor FitzgeraldSet Price TargetBuy$37.00N/A
11/8/2016BCSLower Price TargetN/A
11/2/2016Cantor FitzgeraldReiterated RatingBuy$40.00N/A
9/6/2016Lake Street CapitalReiterated RatingBuy$38.00N/A
7/21/2016Lake Street CapitalInitiated CoverageBuy$38.00N/A
7/19/2016BMO Capital MarketsReiterated RatingBuyN/A
7/1/2016Janney Montgomery ScottReiterated RatingBuy$30.00N/A
6/30/2016Royal Bank of CanadaReiterated RatingBuyN/A
6/30/2016Wells Fargo & CompanyReiterated RatingBuyN/A
6/28/2016BMO Capital MarketsInitiated CoverageOutperform$35.00N/A
(Data available from 6/21/2016 forward)
Flexion Therapeutics logo
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $9.12
Low: $9.01
High: $9.37

50 Day Range

MA: $8.45
Low: $6.99
High: $9.67

52 Week Range

Now: $9.12
Low: $6.71
High: $14.39


20,530 shs

Average Volume

803,489 shs

Market Capitalization

$455.47 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Flexion Therapeutics?

The following equities research analysts have issued research reports on Flexion Therapeutics in the last year: BMO Capital Markets, Credit Suisse Group AG, HC Wainwright, Needham & Company LLC, Northland Securities, Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, The Goldman Sachs Group, Inc., Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for FLXN.

What is the current price target for Flexion Therapeutics?

8 Wall Street analysts have set twelve-month price targets for Flexion Therapeutics in the last year. Their average twelve-month price target is $20.13, suggesting a possible upside of 119.7%. Northland Securities has the highest price target set, predicting FLXN will reach $35.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $14.00 for Flexion Therapeutics in the next year.
View the latest price targets for FLXN.

What is the current consensus analyst rating for Flexion Therapeutics?

Flexion Therapeutics currently has 1 hold rating, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FLXN will outperform the market and that investors should add to their positions of Flexion Therapeutics.
View the latest ratings for FLXN.

What other companies compete with Flexion Therapeutics?

How do I contact Flexion Therapeutics' investor relations team?

Flexion Therapeutics' physical mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company's listed phone number is 781-305-7777 and its investor relations email address is [email protected] The official website for Flexion Therapeutics is